Literature DB >> 12387773

Giardia lamblia infections become clinically evident by eliciting symptoms of irritable bowel syndrome.

Marco D'Anchino1, Dante Orlando, Lucrezia De Feudis.   

Abstract

OBJECTIVES: Giardia lamblia infection is often asymptomatic. Its main, but not well understood, symptom is diarrhea. An outbreak of giardiasis in our town allowed us to test the hypothesis that patients with symptomatic infection are, actually, patients with Irritable Bowel Syndrome (IBS) exacerbated by giardiasis.
METHODS: We studied 100 patients with symptomatic giardiasis. Eighty-two of them were also affected by IBS, according to the "Rome 1992 Criteria". They were randomized in four groups, two of which (A and B), made up of 41 patients each, included the subjects with giardiasis and IBS, whereas the remaining two (C and D), made of up of 9 patients each, included subjects with giardiasis only. The groups A and C were treated with metronidazole, whereas groups B and D were treated with drugs commonly used for IBS, but inactive against the parasite.
RESULTS: According to a single blind protocol, the treatment with metronidazole was ineffective in the groups with giardiasis and IBS. Instead, the treatment for IBS ameliorated the symptoms in these patients. On the contrary, the groups without IBS improved only with metronidazole.
CONCLUSIONS: The large majority of patients with symptomatic giardiasis are affected by IBS and are not cured by antiparasite treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387773     DOI: 10.1016/s0163-4453(02)91038-8

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  15 in total

1.  Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia.

Authors:  Barbara J Davids; Ching M Liu; Elaine M Hanson; Christine H Y Le; Jonathan Ang; Kurt Hanevik; Marvin Fischer; Matej Radunovic; Nina Langeland; Marcela Ferella; Staffan G Svärd; Majid Ghassemian; Yukiko Miyamoto; Lars Eckmann
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  Mechanisms of epithelial dysfunction in giardiasis.

Authors:  Andre G Buret
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

3.  Giardia lamblia-induced changes in gene expression in differentiated Caco-2 human intestinal epithelial cells.

Authors:  Katarina Roxström-Lindquist; Emma Ringqvist; Daniel Palm; Staffan Svärd
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Pit Latrines: A Noninvasive Sampling Strategy to Assess Fecal Pathogen Occurrence in Low Resource Communities.

Authors:  Nathaniel LaHue; Kathleen A Alexander
Journal:  J Community Health       Date:  2018-12

5.  Mast cell-dependent control of Giardia lamblia infections in mice.

Authors:  Erqiu Li; Ping Zhou; Ziva Petrin; Steven M Singer
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Infectious diarrhea: Cellular and molecular mechanisms.

Authors:  Kim Hodges; Ravinder Gill
Journal:  Gut Microbes       Date:  2010-01

7.  Prevalence of recurring symptoms after infection with Giardia lamblia in a non-endemic area.

Authors:  Knut-Arne Wensaas; Nina Langeland; Guri Rortveit
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

Review 8.  Giardia and Cryptosporidium and public health: the epidemiological scenario from the Italian perspective.

Authors:  Annunziata Giangaspero; Federica Berrilli; Olga Brandonisio
Journal:  Parasitol Res       Date:  2007-06-26       Impact factor: 2.289

9.  Infectious causation of chronic disease: examining the relationship between Giardia lamblia infection and irritable bowel syndrome.

Authors:  Alice S Penrose; Eden V Wells; Allison E Aiello
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

Review 10.  Extra-intestinal and long term consequences of Giardia duodenalis infections.

Authors:  Marie C M Halliez; André G Buret
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.